FUJIREBIO

Fujirebio is an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care... Fujirebio started in Japan in 1950. It developed the first TPHA diagnostics kit, the gold standard for syphilis testing, in 1966. Since then, we have built a strong tradition of innovating, developing, manufacturing and marketing high-quality in vitro diagnostics testing solutions worldwide. Over the years, the acquisition of Centocor Diagnostics, CanAg Diagnostics and Innogenetics have further bolstered our capabilities and expertise in various clinical areas. Today, working closely with one of the world's top commercial laboratories (SRL, Inc.), another entity within the H.U. Group, Fujrebio combines expertise and experience for the diagnostics market that is more potent than ever... At Fujirebio Europe N.V. we have always given great..

Also known as: Fujirebio China, Fujirebio China Co., Ltd., Fujirebio Diagnostics Japan, Inc., Fujirebio Diagnostics, Inc., Fujirebio Europe NV, Fujirebio France SARL, Fujirebio Germany GmbH, Fujirebio Holdings, Inc., Fujirebio Iberia S.L.U., Fujirebio Inc., Fujirebio Italia S.r.l., Fujirebio Taiwan Inc., Fujirebio US Inc.

VAT numbers: 0427.550.660

Primary location: Malvern United States